Skip to main content

Table 2 Results from the reference case probabilistic analysis (95% confidence intervals)

From: Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis

Treatment Cost (CAD$) Effect (QALYs) Incremental Cost Incremental Effect ICER
BREN + AVD $411,190 9.62 $192,336 0.46 $418,122
($300,490–$554,715) (7.29–11.0)
ABVD $218,854 9.16
($156,367–$310,743) (6.98–10.49)